Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Ultimovacs ASA (7UM.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
5.77+0.08 (+1.41%)
At close: 09:16AM CEST
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.69
Open5.77
Bid5.54 x N/A
Ask5.75 x N/A
Day's Range5.77 - 5.77
52 Week Range5.69 - 16.50
Volume3
Avg. Volume0
Market Cap202.46M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 7UM.F

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Ultimovacs Announces Plenary Oral Presentation of Phase I Melanoma Trial Results at the 19th International Congress of the Society for Melanoma Research (SMR)

      New clinical data from phase I trial UV1-103, combining UV1 with pembrolizumab in advanced melanoma will be presented Oslo, September 21 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announced today that further data from its clinical study on the combination of its universal cancer vaccine, UV1, and the PD-1 checkpoint inhibitor, pembrolizumab, will be disclosed in an oral presentation at the 19th International Congress of the

    • GlobeNewswire

      Ultimovacs Announces Publication of Phase I Melanoma Trial Data in Journal of Translational Medicine

      Comprehensive characterization of phase I UV1-checkpoint inhibitor combination trialClinical responses seen in patients with favored and less favored baseline characteristicsT cell activation observed post-treatment in tumors of responding patients Oslo, September 12, 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for the treatment of cancer, announced today the publication of data from its phase I melanoma trial in Journal of Translational

    • GlobeNewswire

      Ultimovacs ASA: New share capital registered

      Oslo, 9 September 2022, Ultimovacs ASA (the "Company") refers to the announcement published on 5 September 2022 regarding the issuance of new shares in connection with the Company's employee incentive program. The share capital increase related to the share issue of 44,000 new shares has been registered in the Norwegian Register of Business Enterprises, and the Company's new share capital is NOK 3,426,576.10, divided into 34,265,761 shares, each with a par value of NOK 0.10. For further informat

    Advertisement
    Advertisement